Hot Products
Catalog No. | Information |
CFN98698 | Cryptomeridiol Cryptomeridiol is a potential skin-whitening agent, exhibits melanogenesis inhibitory activity on α-MSH-stimulated B16 melanoma cells. Cryptomeridiol has low activity against A. niger, T. mentagrophytes, and C. albicans. (-)-Cryptomeridiol also exhibits a significant and concentration-dependent inhibitory effect on PAF receptor binding, with inhibitory concentration (IC)(50) values of 17.5 uM. |
CFN98478 | Cryptotanshinone Cryptotanshinone is a potent STAT3 inhibitor with IC50 of 4.6 μM, and inhibits STAT3 Tyr705 phosphorylation in DU145 prostate cancer cells. It is also an AR inhibitor to suppress androgen/AR-mediated cell growth and PSA expression by blocking AR dimerization and the AR-coregulator complex formation. Cryptotanshinone has anti-atherosclerosis, neuroprotective, anti-cancer,and anti-neointimal formation activities. Cryptotanshinone reverses DEX-induced androgen excess and ovarian IR in mice through activation of insulin signaling and the regulation of glucose transporters and hormone-synthesizing enzymes, it has an inhibitory effect on MMP-9 production and migration of human aortic smooth muscle cells treated with TNF-alpha in a dose-dependent manner. |
CFN70261 | Cubebin Cubebin showes anti-inflammatory, and anticancer activities. It also shows neuroprotective effects, this could be attributed to its brain AChE inhibition and antioxidant activity. |
CFN90324 | Cucurbitacin A Cucurbitacin I, cytotoxic triterpenoid sterols isolated from plants, elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-Kinase. |
CFN99129 | Cucurbitacin B Cucurbitacin B, an effective HIF-1 inhibitor, has antitumor activity, it inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. It inhibited AKT signaling activation through up-regulation of PTEN. |
CFN92141 | Cucurbitacin B 2-O-beta-D-glucoside Cucurbitacin B 2-o-β-D-glucoside has anticancer activity. |
CFN90209 | Cucurbitacin D Cucurbitacin D has anticancer effects, it induces apoptosis through caspase-3 and phosphorylation of JNK in hepatocellular carcinoma cells. Cucurbitacin D may be a potential therapeutic agent for β-hemoglobinopathies, including sickle cell anemia and β-thalassemia. Cucurbitacin D is a new inflammasome activator in macrophages, it can initiate immunomodulating activity in macrophages to lead to inflammasome activation as well as enhancement of LPS signaling. |
CFN90154 | Cucurbitacin E Cucurbitacin E has prevention of neurodegeneration, it has potent anti-proliferative, antineoplastic, anti-inflammatory and analgesic actions, it also exhibits immunosuppressive effect by attenuating critical cytokine expression through down-regulating the NF-κB signaling pathway. |
CFN70316 | Cucurbitacin I Cucurbitacin I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells. Cucurbitacin I elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-kinase, it promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma. Cucurbitacin I may inhibit P-gp-mediated transport and interact with P-gp substrates in the intestinal absorption process. |
CFN98171 | Cucurbitacin IIA Cucurbitacin IIa has anti-cancer, anti-bacterial, and anti-inflammatory effects, it can induce apoptosis and enhance autophagy; it also can disrupt the actin cytoskeleton and direct the cell to undergo PARP-mediated apoptosis through the inhibition of survivin downstream of JAK2/STAT3. |